246 related articles for article (PubMed ID: 18794647)
1. The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans.
O'Mathúna B; Farré M; Rostami-Hodjegan A; Yang J; Cuyàs E; Torrens M; Pardo R; Abanades S; Maluf S; Tucker GT; de la Torre R
J Clin Psychopharmacol; 2008 Oct; 28(5):523-9. PubMed ID: 18794647
[TBL] [Abstract][Full Text] [Related]
2. Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans.
Yubero-Lahoz S; Pardo R; Farré M; O'Mahony B; Torrens M; Mustata C; Pérez-Mañá C; Carbó ML; de la Torre R
Clin Pharmacokinet; 2011 May; 50(5):319-29. PubMed ID: 21456632
[TBL] [Abstract][Full Text] [Related]
3. The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy).
Van LM; Heydari A; Yang J; Hargreaves J; Rowland-Yeo K; Lennard MS; Tucker GT; Rostami-Hodjegan A
J Psychopharmacol; 2006 Nov; 20(6):834-41. PubMed ID: 16478752
[TBL] [Abstract][Full Text] [Related]
4. Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA.
Yang J; Jamei M; Heydari A; Yeo KR; de la Torre R; Farré M; Tucker GT; Rostami-Hodjegan A
J Psychopharmacol; 2006 Nov; 20(6):842-9. PubMed ID: 16714321
[TBL] [Abstract][Full Text] [Related]
5. Kinetics of the time-dependent inactivation of CYP2D6 in cryopreserved human hepatocytes by methylenedioxymethamphetamine (MDMA).
Van LM; Swales J; Hammond C; Wilson C; Hargreaves JA; Rostami-Hodjegan A
Eur J Pharm Sci; 2007 May; 31(1):53-61. PubMed ID: 17387004
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Ecstasy influence on tramadol and its main metabolite plasma concentration in rats.
Jamali B; Sheikholeslami B; Hosseinzadeh Ardakani Y; Lavasani H; Rouini MR
Drug Metab Pers Ther; 2017 Sep; 32(3):137-145. PubMed ID: 28917081
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of CYP2D6 by methylenedioxymethamphetamine in different recombinant expression systems.
Van LM; Hargreaves JA; Lennard MS; Tucker GT; Rostami-Hodjegan A
Eur J Pharm Sci; 2007 Sep; 32(1):8-16. PubMed ID: 17574396
[TBL] [Abstract][Full Text] [Related]
8. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.
Aarnoutse RE; Kleinnijenhuis J; Koopmans PP; Touw DJ; Wieling J; Hekster YA; Burger DM
Clin Pharmacol Ther; 2005 Dec; 78(6):664-74. PubMed ID: 16338282
[TBL] [Abstract][Full Text] [Related]
9. Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe.
Segura M; Farré M; Pichini S; Peiró AM; Roset PN; Ramírez A; Ortuño J; Pacifici R; Zuccaro P; Segura J; de la Torre R
Clin Pharmacokinet; 2005; 44(6):649-60. PubMed ID: 15910012
[TBL] [Abstract][Full Text] [Related]
10. Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine.
Heydari A; Yeo KR; Lennard MS; Ellis SW; Tucker GT; Rostami-Hodjegan A
Drug Metab Dispos; 2004 Nov; 32(11):1213-7. PubMed ID: 15328252
[TBL] [Abstract][Full Text] [Related]
11. Changes in CYP1A2 activity in humans after 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) administration using caffeine as a probe drug.
Yubero-Lahoz S; Pardo R; Farre M; Mathuna BÓ; Torrens M; Mustata C; Perez-Mañá C; Langohr K; Carbó ML; de la Torre R
Drug Metab Pharmacokinet; 2012; 27(6):605-13. PubMed ID: 22673010
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans.
Mas M; Farré M; de la Torre R; Roset PN; Ortuño J; Segura J; Camí J
J Pharmacol Exp Ther; 1999 Jul; 290(1):136-45. PubMed ID: 10381769
[TBL] [Abstract][Full Text] [Related]
13. Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance.
Borges S; Li L; Hamman MA; Jones DR; Hall SD; Gorski JC
Drug Metab Dispos; 2005 Jul; 33(7):1052-5. PubMed ID: 15821042
[TBL] [Abstract][Full Text] [Related]
14. Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine).
Pizarro N; Farré M; Pujadas M; Peiró AM; Roset PN; Joglar J; de la Torre R
Drug Metab Dispos; 2004 Sep; 32(9):1001-7. PubMed ID: 15319342
[TBL] [Abstract][Full Text] [Related]
15. Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro.
Ramamoorthy Y; Yu AM; Suh N; Haining RL; Tyndale RF; Sellers EM
Biochem Pharmacol; 2002 Jun; 63(12):2111-9. PubMed ID: 12110370
[TBL] [Abstract][Full Text] [Related]
16. Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice.
Jurica J; Bartecek R; Zourkova A; Pindurova E; Sulcova A; Kasparek T; Zendulka O
J Clin Pharm Ther; 2012 Aug; 37(4):486-90. PubMed ID: 22548589
[TBL] [Abstract][Full Text] [Related]
17. Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity.
Hu OY; Tang HS; Lane HY; Chang WH; Hu TM
J Pharmacol Exp Ther; 1998 Jun; 285(3):955-60. PubMed ID: 9618394
[TBL] [Abstract][Full Text] [Related]
18. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine.
Abdel-Rahman SM; Marcucci K; Boge T; Gotschall RR; Kearns GL; Leeder JS
Drug Metab Dispos; 1999 Jul; 27(7):770-5. PubMed ID: 10383919
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition.
Schadel M; Wu D; Otton SV; Kalow W; Sellers EM
J Clin Psychopharmacol; 1995 Aug; 15(4):263-9. PubMed ID: 7593709
[TBL] [Abstract][Full Text] [Related]
20. Influence of phenylalanine 120 on cytochrome P450 2D6 catalytic selectivity and regiospecificity: crucial role in 7-methoxy-4-(aminomethyl)-coumarin metabolism.
Keizers PH; Lussenburg BM; de Graaf C; Mentink LM; Vermeulen NP; Commandeur JN
Biochem Pharmacol; 2004 Dec; 68(11):2263-71. PubMed ID: 15498516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
